This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

EYLEA® (aflibercept) 8 mg real-world evidence

12-month real-world outcomes in patients with DMO

Imperial College Healthcare NHS Trust

DMO

These data are from real patients. Individual results may vary.

Study design:
Retrospective observational audit evaluated outcomes in 26 treatment-naïve eyes and 49 previously treated eyes with DMO. All eyes were initiated on or switched to EYLEA 8 mg between March 2024 and August 2025.

Treatment-naïve eyes received EYLEA 8 mg loading injections (initiated with one injection per month for three consecutive doses), followed by a T&E protocol.
Previously treated eyes included in this cohort had suboptimal response to previous anti-VEGF agent and/or IVT steroid therapy. Eyes received EYLEA 8 mg loading injections (initiated with one injection per month for three consecutive doses), followed by a T&E protocol.

Patient demographics

Eyes, N	
Treatment-naïve	26
Previously treated	49
Mean age, years	
Treatment-naïve	60.1
Previously treated	63.5
Female, %	
Treatment-naïve	36.9
Previously treated	47.8

Treatment-naïve patients

Extended treatment intervals with EYLEA 8 mg

Longest treatment interval from baseline through Month 12



~8 in 10
patients achieved intervals of ≥q12 (N=20/26)

16.5 weeks
Mean longest interval from baseline through Month 12 (N=26)



~5 in 10
patients achieved intervals of ≥q16 (N=12/26)

Sustained drying
with EYLEA 8 mg

Change in CFT over time



−103 µm
Change in mean CFT with EYLEA 8 mg

Meaningful vision gains
with EYLEA 8 mg

Change in BCVA over time



+6.0 ETDRS letters
Change in mean BCVA with EYLEA 8 mg

No serious ocular or systemic adverse events were reported, including no cases of endophthalmitis or significant rises in IOP

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.
Figures do not show all time points analysed (after 6 months and after 9 months data are not included).

Abbreviations:
BCVA, best corrected visual acuity; **CFT**, central foveal thickness; **DMO**, diabetic macular oedema; **ETDRS**, Early Treatment Diabetic Retinopathy Study; **IOP**, intraocular pressure; **IVT**, intravitreal; **qX**, every X weeks; **T&E**, treat-and-extend; **VEGF**, vascular endothelial growth factor.

Reference:
Bayer UK Data on File_PP-EYL-GB-3034_November 2025

May 2026 | PP-EYL_8mg-GB-1035

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

DMO

Previously treated patients

Extended treatment intervals with EYLEA 8 mg

Longest treatment interval from baseline through Month 12



~7 in 10
patients achieved intervals of ≥q12 (N=33/49)

13.7 weeks
Mean longest interval from baseline through Month 12 (N=49)



~4 in 10
patients achieved intervals of ≥q16 (N=18/49)

Sustained drying with EYLEA 8 mg

Change in CFT over time



–52 µm
Mean change in CFT with EYLEA 8 mg (N=49)

Maintained vision with EYLEA 8 mg

Change in BCVA over time



+1.1
ETDRS letters
Mean change in BCVA with EYLEA 8 mg (N=49)

No serious ocular or systemic adverse events were reported, including no cases of endophthalmitis or significant rises in IOP

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.
Figures do not show all time points analysed (8 weeks after third injection and after 9 months data are not included).

Abbreviations:
BCVA, best corrected visual acuity; **CFT**, central foveal thickness; **DMO**, diabetic macular oedema; **ETDRS**, Early Treatment Diabetic Retinopathy Study; **IOP**, intraocular pressure; **qX**, every X weeks.

Reference:
Bayer UK Data on File_PP-EYL-GB-3034_November 2025

May 2026 | PP-EYL_8mg-GB-1035

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.